| |
 |
|
Class Information
Number: 424/130.1
Name: Drug, bio-affecting and body treating compositions > Immunoglobulin, antiserum, antibody, or antibody fragment, except conjugate or complex of the same with nonimmunoglobulin material
Description: Subject matter involving an immunoglobulin, an antiserum, an antibody, or an antibody fragment, except a conjugate or a complex of the same with a nonimmunoglobulin material.
Sub-classes under this class:
| Class Number |
Class Name |
Patents |
| 424/131.1 |
Anti-idiotypic |
135 |
| 424/171.1 |
Binds allergen or component thereof |
14 |
| 424/139.1 |
Binds antigen or epitope whose amino acid sequence is disclosed in whole or in part (e.g., binds specifically-identified amino acid sequence, etc.) |
673 |
| 424/163.1 |
Binds antigens of multiple bacterial species (e.g., multivalent antiserum that binds antigens of multiple bacterial species, etc.) |
48 |
| 424/164.1 |
Binds bacterium or component thereof or substance produced by said bacterium |
224 |
| 424/172.1 |
Binds eukaryotic cell or component thereof or substance produced by said eukaryotic cell (e.g., honey, etc.) |
232 |
| 424/138.1 |
Binds expression product or fragment thereof of cancer-related gene (e.g., oncogene, proto-oncogene, etc.) |
326 |
| 424/175.1 |
Binds hapten, hapten-carrier complex, or specifically-identified chemical structure (e.g., drug, etc.) |
56 |
| 424/158.1 |
Binds hormone or other secreted growth regulatory factor, differentiation factor, or intercellular mediator (e.g., cytokine, vascular permeability factor, etc.); or binds serum protein, plasma protein, fibrin, or enzyme |
344 |
| 424/137.1 |
Binds specifically-identified oligosaccharide structure |
147 |
| 424/159.1 |
Binds virus or component thereof |
132 |
| 424/132.1 |
Derived from transgenic multicellular eukaryote (e.g., plant, etc.) |
21 |
| 424/157.1 |
Derived from, or present in, food product (e.g., milk, colostrum, whey, eggs, etc.) |
102 |
| 424/140.1 |
Extracorporeal or ex vivo removal of antibodies or immune complexes (e.g., removal of autoantibodies, etc.); or extracorporeal or ex vivo removal of antigen by antibodies (e.g., removal of cancer cells from bone marrow by antibodies, etc.) |
95 |
| 424/176.1 |
Free from infectious agents (e.g., viruses or bacteria removed or inactivated, etc.) |
76 |
| 424/141.1 |
Monoclonal antibody or fragment thereof (i.e., produced by any cloning technology) |
1,213 |
| 424/177.1 |
Reduced antigenicity, reduced ability to bind complement, or reduced numbers of activated complement components (e.g., free from aggregated, denatured, fragmented, or polymerized immunoglobulins; free from proteolytic enzymes, etc.) |
106 |
| 424/133.1 |
Structurally-modified antibody, immunoglobulin, or fragment thereof (e.g., chimeric, humanized, cdr-grafted, mutated, etc.) |
1,074 |
Patents under this class:
| Patent Number |
Title Of Patent |
Date Issued |
| 7619069 |
Antibodies to TGF-beta 1 |
Nov. 17, 2009 |
| 7619068 |
Ovr110 antibody compositions and methods of use |
Nov. 17, 2009 |
| 7618633 |
Antibodies that bind CD40 and methods of treating cancer and enhancing immune responses |
Nov. 17, 2009 |
| 7618631 |
Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs |
Nov. 17, 2009 |
| 7618628 |
CD16A binding proteins and use for the treatment of immune disorders |
Nov. 17, 2009 |
| 7618627 |
Method of increasing radiation sensitivity by inhibition of beta one integrin |
Nov. 17, 2009 |
| 7618626 |
Combination treatment for non-hematologic malignancies |
Nov. 17, 2009 |
| 7618625 |
Compositions comprising large and small binding fragments of antibodies against the same toxin |
Nov. 17, 2009 |
| 7618624 |
Weight control using an anti-lipase antibody |
Nov. 17, 2009 |
| 7615616 |
Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby |
Nov. 10, 2009 |
| 7615372 |
Antibodies with immune effector activity and that internalize in endosialin-positive cells |
Nov. 10, 2009 |
| 7615222 |
Enriched antibody for detecting mycobacterial infection, methods of use and diagnostic test employing same |
Nov. 10, 2009 |
| 7615219 |
Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia |
Nov. 10, 2009 |
| 7615218 |
Methods for determining and lowering caffeine concentration in fluids |
Nov. 10, 2009 |
| 7615212 |
Compositions and methods for the systemic treatment of arthritis |
Nov. 10, 2009 |
| 7615211 |
CD70 inhibition for the treatment and prevention of inflammatory bowel disease |
Nov. 10, 2009 |
| 7615210 |
Treatment of endometriosis |
Nov. 10, 2009 |
| 7612179 |
antibodies binding to a C-terminal fragment of apoliopoprotein E |
Nov. 3, 2009 |
| 7611708 |
Methods of therapy for B-cell malignancies using antagonist anti-CD40 antibodies |
Nov. 3, 2009 |
| 7611706 |
RG1 antibodies and uses thereof |
Nov. 3, 2009 |
| 7611705 |
Anti-IL-20 antibody and its use in treating IL-20 associated inflammatory diseases |
Nov. 3, 2009 |
| 7611703 |
Kidney disease targets and uses thereof |
Nov. 3, 2009 |
| 7611702 |
TNF-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy |
Nov. 3, 2009 |
| RE40948 |
APC antibodies |
Oct. 27, 2009 |
| 7608696 |
IBC-1 (invasive breast cancer-1), a putative oncogene amplified in breast cancer |
Oct. 27, 2009 |
| 7608413 |
Kidney disease targets and uses thereof |
Oct. 27, 2009 |
| 7608405 |
Method of selectively assaying adiponectin multimers |
Oct. 27, 2009 |
| 7608404 |
Disease determination method, data generation method for disease determination and data generation system for disease determination |
Oct. 27, 2009 |
| 7608269 |
Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
Oct. 27, 2009 |
| 7608263 |
RG1 antibodies and uses thereof |
Oct. 27, 2009 |
| 7608260 |
Stabilized immunoglobulins |
Oct. 27, 2009 |
| 7608259 |
Methods of cancer diagnosis and therapy targeted against a cancer stem line |
Oct. 27, 2009 |
| 7608247 |
Use of outer membrane protein a in treatment/prevention/diagnosis of bacterial infection in central nervous system and/or peripheral blood circulation |
Oct. 27, 2009 |
| 7608246 |
Apolipoprotein E as an adjuvant for lipid antigens |
Oct. 27, 2009 |
| 7605233 |
Tumour necrosis factor binding ligands |
Oct. 20, 2009 |
| 7604953 |
Bioamplification for microbial sensor signal transduction |
Oct. 20, 2009 |
| 7604801 |
Methods for detecting parvovirus infections |
Oct. 20, 2009 |
| 7604800 |
Anti-PSGL-1 antibodies |
Oct. 20, 2009 |
| 7601357 |
Targeting of long chain triacylglycerol hydrolase gene for tuberculosis treatment |
Oct. 13, 2009 |
| 7601352 |
Monoclonal antibodies and antigen binding fragments thereof capable of binding TrkA and inhibiting the functional activation of TrkA |
Oct. 13, 2009 |
| 7601350 |
Antibodies that bind M. tuberculosis polypeptides |
Oct. 13, 2009 |
| 7601349 |
GIPs, a family of polypeptides with transcription factor activity that interact with Goodpasture antigen binding protein |
Oct. 13, 2009 |
| 7601348 |
Method of examining colon cancer and colon adenoma |
Oct. 13, 2009 |
| 7598046 |
Use of prion conversion modulating agents |
Oct. 6, 2009 |
| 7597896 |
Composition comprising a protein encoded by a modified ERP gene of Mycobacterium |
Oct. 6, 2009 |
| 7597893 |
Human monoclonal antibody specific lipopolysaccharides (LPS) of serotype IATS 06 of Pseudomonas aeruginosa |
Oct. 6, 2009 |
| 7597891 |
Synthesis of human secretory IgA for the treatment of Clostridium difficile associated diseases |
Oct. 6, 2009 |
| 7597888 |
Glycoprotein VI and uses thereof |
Oct. 6, 2009 |
| 7597887 |
KIM-1 antagonists and use to modulate immune system |
Oct. 6, 2009 |
| 7597886 |
Tumor necrosis factor-gamma |
Oct. 6, 2009 |
|
|
|
